U.S. Supreme Court Rejects Teva Pharmaceutical Industries Limited's Copaxone Petition
A U.S. Supreme Court justice on Wednesday declined a request from Teva Pharmaceutical Industries for a stay of an appeals court ruling that would strip the company's $4 billion-a-year multiple sclerosis drug Copaxone of patent protection in 2014, rather than in 2015. In July, the U.S. Court of Appeals for the Federal Circuit issued a decision in a patent fight that pits Teva against two teams developing cheaper generic forms of Copaxone: one with Novartis AG and Momenta Pharmaceuticals Inc ; and another between Mylan Inc and Natco Pharma Ltd .
Help employers find you! Check out all the jobs and post your resume.